Oncotarget

Research Papers:

siRNA knockdown of mitochondrial thymidine kinase 2 (TK2) sensitizes human tumor cells to gemcitabine

Christine Di Cresce _, Rene Figueredo, Mateusz Rytelewski, Saman Maleki Vareki, Colin Way, Peter J. Ferguson, Mark D. Vincent and James Koropatnick

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:22397-22409. https://doi.org/10.18632/oncotarget.4272

Metrics: PDF 1084 views  |   HTML 1502 views  |   ?  


Abstract

Christine Di Cresce1,5, Rene Figueredo2,5, Mateusz Rytelewski1,5, Saman Maleki Vareki1,5, Colin Way1,5, Peter J. Ferguson2,5, Mark D. Vincent2,5, James Koropatnick1,2,3,4,5

1Department of Microbiology and Immunology, The University of Western Ontario, London, Ontario, Canada

2Department of Oncology, The University of Western Ontario, London, Ontario, Canada

3Department of Pathology, The University of Western Ontario, London, Ontario, Canada

4Department of Physiology and Pharmacology, The University of Western Ontario, London, Ontario, Canada

5Cancer Research Laboratory Program, Lawson Health Research Institute and London Regional Cancer Program, London, Ontario, Canada

Correspondence to:

James Koropatnick, e-mail: jkoropatnick@gmail.com

Keywords: cancer, gemcitabine, thymidine kinase, deoxycytidine kinase, mitochondria

Received: January 27, 2015     Accepted: June 03, 2015     Published: June 15, 2015

ABSTRACT

Nucleoside metabolism enzymes are determinants of chemotherapeutic drug activity. The nucleoside salvage enzyme deoxycytidine kinase (dCK) activates gemcitabine (2′, 2′-difluoro-2′-deoxycytidine) and is negatively regulated by deoxycytidine triphosphate (dCTP). Reduction of dCTP in tumor cells could, therefore, enhance gemcitabine activity. Mitochondrial thymidine kinase 2 (TK2) phosphorylates deoxycytidine to generate dCTP. We hypothesized that: (1) TK2 modulates human tumor cell sensitivity to gemcitabine, and (2) antisense knockdown of TK2 would decrease dCTP and increase dCK activity and gemcitabine activation. siRNA downregulation of TK2 sensitized MCF7 and HeLa cells (high and moderate TK2) but not A549 cells (low TK2) to gemcitabine. Combined treatment with TK2 siRNA and gemcitabine increased dCK. We also hypothesized that TK2 siRNA-induced drug sensitization results in mitochondrial damage that enhances gemcitabine effectiveness. TK2 siRNA and gemcitabine decreased mitochondrial redox status, DNA content, and activity. This is the first demonstration of a direct role for TK2 in gemcitabine resistance, or any independent role in cancer drug resistance, and further distinguishes TK2 function from that of other dTMP-producing enzymes [cytosolic TK1 and thymidylate synthase (TS)]. siRNA knockdown of TK1 and/or TS did not sensitize cancer cells to gemcitabine indicating that, among the 3 enzymes, only TK2 is a candidate therapeutic target for combination with gemcitabine.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 4272